ADC Therapeutics Completes Enrollment In LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating ZYNLONTA In Combination With Bispecific Antibody Glofitamab In Patients With R/R Diffuse Large B-Cell Lymphoma

Loading news article.

ADC Therapeutics Completes Enrollment In LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating ZYNLONTA In Combination With Bispecific Antibody Glofitamab In Patients With R/R Diffuse Large B-Cell Lymphoma | WAPE

ADC Therapeutics Completes Enrollment In LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating ZYNLONTA In Combination With Bispecific Antibody Glofitamab In Patients With R/R Diffuse Large B-Cell Lymphoma

Article summary

Related companies

Comments —